These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 20149423)

  • 1. "Importance of delivered cycles and nomogram for intraperitoneal chemotherapy in ovarian cancer".
    Markman M
    Gynecol Oncol; 2010 May; 117(2):390; author reply 391. PubMed ID: 20149423
    [No Abstract]   [Full Text] [Related]  

  • 2. Importance of delivered cycles and nomogram for intraperitoneal chemotherapy in ovarian cancer.
    Yen MS; Twu NF; Lai CR; Horng HC; Chao KC; Juang CM
    Gynecol Oncol; 2009 Sep; 114(3):415-9. PubMed ID: 19577277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
    Gray HJ; Shah CA; Swensen RE; Tamimi HK; Goff BA
    Gynecol Oncol; 2010 Mar; 116(3):340-4. PubMed ID: 19922987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy delivered into abdomen may extend ovarian cancer survival.
    Mayo Clin Womens Healthsource; 2006 Jun; 10(6):3. PubMed ID: 16675917
    [No Abstract]   [Full Text] [Related]  

  • 5. The port: delivering intraperitoneal chemotherapy in ovarian cancer.
    Doane LS
    Todays OR Nurse; 1992 Sep; 14(9):11-8. PubMed ID: 1412628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intraperitoneal chemotherapy for ovarian cancer.
    de Castro G; Snitcovsky IM; Federico MH
    N Engl J Med; 2006 Apr; 354(15):1641-3; author reply 1641-3. PubMed ID: 16615184
    [No Abstract]   [Full Text] [Related]  

  • 7. Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer.
    Marth C; Walker JL; Barakat RR; Casado A; Gadducci A; Miller B; Odicino F; Pujade-Lauraine E; Sehouli J; Tropé C; Wenzel L; Zeimet AG
    Cancer; 2007 Feb; 109(4):645-9. PubMed ID: 17238177
    [No Abstract]   [Full Text] [Related]  

  • 8. [Intraperitoneal chemotherapy through implantable injection port in patients with advanced ovarian (or tubal) carcinoma].
    Ryuko K; Iwanari O; Moriyama M; Moriyama M; Nakayama S; Miyako J; Kitao M
    Gan To Kagaku Ryoho; 1991 Aug; 18(11):2052-7. PubMed ID: 1877848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraperitoneal antineoplastic agents in the management of ovarian cancer.
    Tropé C; Kaern J; Vergote I
    Eur J Surg Suppl; 1991 May; (561):83-6. PubMed ID: 1720054
    [No Abstract]   [Full Text] [Related]  

  • 10. Intraperitoneal chemotherapy comes of age.
    Cannistra SA
    N Engl J Med; 2006 Jan; 354(1):77-9. PubMed ID: 16394306
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: "Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study".
    Markman M
    Gynecol Oncol; 2007 Apr; 105(1):279-80; author reply 280-1. PubMed ID: 17291570
    [No Abstract]   [Full Text] [Related]  

  • 12. [A case of stage IVb ovarian carcinoma successfully treated with intra-arterial infusion chemotherapy using implantable reservoir system].
    Kobayashi O; Kuwae C; Kohyama A; Yorinaga Y; Sudo H; Kitada H; Otsuka H; Minami T
    Gan To Kagaku Ryoho; 1992 Aug; 19(10 Suppl):1697-700. PubMed ID: 1530335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel.
    Ozols RF; Bookman MA; du Bois A; Pfisterer J; Reuss A; Young RC
    Gynecol Oncol; 2006 Oct; 103(1):1-6. PubMed ID: 16904166
    [No Abstract]   [Full Text] [Related]  

  • 14. An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.
    Berry E; Matthews KS; Singh DK; Buttin BM; Lurain JR; Alvarez RD; Schink J
    Gynecol Oncol; 2009 Apr; 113(1):63-7. PubMed ID: 19201457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study.
    Chan JK; Tian C; Fleming GF; Monk BJ; Herzog TJ; Kapp DS; Bell J
    Gynecol Oncol; 2010 Mar; 116(3):301-6. PubMed ID: 19945740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose chemotherapy and hematopoietic progenitor cell support for patients with epithelial ovarian cancer.
    Kotz KW; Schilder RJ
    Semin Oncol; 1995 Jun; 22(3):250-62. PubMed ID: 7777869
    [No Abstract]   [Full Text] [Related]  

  • 17. [Ovarian carcinoma: various aspects of intraperitoneal chemotherapy].
    Los G; Beijnen JH; Dubbelman R; ten Bokkel Huinink WW; McVie JG
    Ned Tijdschr Geneeskd; 1988 Jul; 132(29):1347-50. PubMed ID: 3412503
    [No Abstract]   [Full Text] [Related]  

  • 18. [Ovarian cancer treatment from the standpoint of the gynecologic oncologist].
    Sugiyama T; Yoshizaki A; Hatayama S
    Gan To Kagaku Ryoho; 2007 Jul; 34(7):1011-6. PubMed ID: 17637537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re: intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.
    Petru E; Benedicic Ch; Huell A
    Gynecol Oncol; 2006 Jul; 102(1):129; author reply 130. PubMed ID: 16600354
    [No Abstract]   [Full Text] [Related]  

  • 20. Intraperitoneal therapy for ovarian cancer: why has it not become standard?
    Rowan K
    J Natl Cancer Inst; 2009 Jun; 101(11):775-7. PubMed ID: 19470952
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.